CURRICULUM VITAE PERSONAL DATA Name:
Richard Robert Neubig
EDUCATION 1967-71 1971-75 1975-81 1977-81
Portage Northern High School, Portage, Michigan University of Michigan, Ann Arbor, B.S. (Chemistry) Harvard Medical School, Harvard-M.I.T. Program in Health Sciences and Technology, Boston, MA, M.D. Harvard University, Cambridge, MA, Ph.D. (Pharmacology, Advisor Jonathan B. Cohen)
POSTDOCTORAL TRAINING 1981-84
House Officer I-III, Department of Internal Medicine, University Hospital, Ann Arbor, MI
ACADEMIC APPOINTMENTS 1994-
Professor, Department of Pharmacology, The University of Michigan
1990-
Associate Professor, Department of Internal Medicine (Division of Cardiovascular Medicine), The University of Michigan
1989-1994
Associate Professor, Department of Pharmacology, The University of Michigan
1984-89
Assistant Professor, Department of Internal Medicine (Division of Hypertension), The University of Michigan
1984-89
Assistant Professor, Department of Pharmacology, The University of Michigan
1983-84
Instructor, The Department of Pharmacology, The University of Michigan
ADMINISTRATIVE POSITIONS 20042012-
Co-Director, Center for Chemical Genomics Director, Center for the Discovery of New Medicines
1
SENIOR POSTDOCTORAL TRAINING 1991
Sabbatical: The University of Michigan, Ann Arbor, MI. Department of Biological Chemistry, Geneva M. Omann. Fluorescence studies of neutrophil chemotactic receptors.
1992
Sabbatical: University of New Mexico and Los Alamos National Lab, Larry A. Sklar. Fluorescence studies of neutrophil chemotactic receptors.
1992
Sabbatical: The University of Michigan, Ann Arbor, MI. Department of Biophysics, Eric Zuiderweg. NMR structural analysis of synthetic receptor peptides.
2003
Sabbatical: The University of Michigan, Ann Arbor, MI. Department of Pharmacology, Roger Sunahara. High level expression and biophysical analysis of G protein coupled receptors.
CONSULTING POSITIONS 1994-2002 1995-2005 2001 2001 2001-2002 2002 2001-2003 2002 2003-2005 2005-2006 2005-2006 2005-2007 20072009-
GraphPad Software, Scientific Advisory Board (San Diego, CA) Pfizer, Institutional Review Board (Ann Arbor, MI) Wyeth-Ayerst Research (Princeton, NJ) Inspire Pharmaceuticals (Raleigh, NC) Pfizer, Cardiovascular Research (Ann Arbor, MI) Millennium Pharmaceuticals (Cambridge, MA) Global Village Communications (Sitemaker) DiscoveRx (San José, CA) Adolor Corp. (Exton, PA) Cephalon Inc. (Frazer, PA), Scientific Advisory Board Striatus LLC (Dexter, MI) Berlex (Richmond, CA) Intellicyt (Albuquerque, NM) Bristol Myers Squibb (New York, NY)
SCIENTIFIC ACTIVITIES Editorial Boards 199220052000-2011 1992-97
Molecular Pharmacology (Associate Editor, 1996-2000) Chemical Biology & Drug Design Molecular Interventions Journal of Biological Chemistry
Reviewer American Journal of Physiology Biochemical Pharmacology
Biochemistry Brain Research 2
Cell & Molecular Biology Chemistry & Biology Circulation CRC Press European Journal of Neuroscience FASEB Journal Hypertension Journal of Pharmacology and Experimental Therapeutics
Journal of Theoretical Biology Nature Nature Methods Nature Reviews Drug Discovery Neuropsychophparmacology Pediatric Research Proceedings of the National Academy of Sciences Science
Study Sections/Review Panels 2012 2011 2010 2007-2010 2009 2008 2006 1996-2000 1992 1990 1989
NIH Review Panels: NCATS X02 PAR-12-203 Therapeutic Uses for Existing Molecules ZRG1 MDCN-N (04) Special Emphasis Panel NIH Director’s New Innovator Awards Review Panel NIH Molecular and Integrative Signal Transduction (MIST) Study Section (Chair 2007-2009) ZCA1 RTRB-H - NCI P30 Competitive Revision Study section ZRG1 BST-Q (51) Roadmap Assay Development Study Section, Ad hoc, April 2006 Cell signaling and dynamics (CSD), Ad hoc, June 2006 NIH Pharmacology (PHRA) Study Section (Chairman 1999-2000) NCI Program Project Site Visitor, Bozeman, MT Toxicology Study Section (ad hoc) NHLBI Program Project Site Visitor
Other reviewing WPI (World Premier International research center initiative), Tsukuba University, Japan. (Masashi Yanigasawa, Director) 2012 University of Washington, Pharmacology Graduate Program 2008 University of North Carolina, Pharmacology Graduate Program 2007 & 2009 NIAID, Board of Scientific Counselors (Ad hoc), Laboratory of Immunoregulation (Dr. Anthony Fauci) 2006 Signal Transduction Review Working Group 2003-2006 AHA Molecular Signaling 2, Study Section 2002 Grant Reviewer, NSERC, Canada, 2002 Grant Reviewer, Ad hoc NHLBI review chair 2002 DOE, SBIR Grant Reviewer 2001 NINDS Board of Scientific Counselors (ad hoc) 2000 Grant Reviewer, Ad hoc NHLBI review chair 2000 Grant Reviewer, VA Merit Review Applications 2000 Grant Reviewer, University of Leuven, Belgium Research Fund 1997-1998 Mid-America Research Consortium, Peer Review Committee 1990-91 American Heart Association of Michigan, Peer Review Committee 1995 Grant Reviewer, National Science Foundation 1994 Grant Reviewer, Israel Science Foundation 2013
3
1991
Grant Reviewer, Wellcome Trust, London, UK
Society Leadership 2012-2013 2009-2012 1997-1999 1994-1997
President-Elect, ASPET Councilor, ASPET Chair, ASPET Division for Molecular Pharmacology, Executive Committee Chair, ASPET Section for Molecular Pharmacology
Meetings/Symposia Organized 2013 2011 2009 2008 2006 2006 2002 1996 1991 1990
EB ’13 Sympsoium “Systems Biology Approaches to Pharmacologic Problems” EB ’11 Sympsium “Gα Subtype-Selective Signaling by GPCRs as a Substrate for Functional Selectivity” Gordon Research Conference, G Proteins and Protein Phosphorylation (with Ken Harden, UNC) EB08 RGS Colloquium (with Michael Koelle, Yale University) Great Lakes GPCR Retreat/7TM Club, Ann Arbor, MI (with Roger Sunahara and John Tesmer) UM Single Molecule Symposium, June 2006 (Nils Walter, lead) Great Lakes GPCR Retreat/7TM Club, Ann Arbor, MI (with Roger Sunahara) EB '96, Washington, D.C., Workshop on "G Protein Techniques" FASEB, Atlanta, GA, Symposium on Dynamics of Receptor Signalling BMRC Symposium, Ann Arbor, MI "Structural Basis of Ligand-Regulated Protein Function"
GRANT SUPPORT Current:
National Institutes of Health R01 GM39561-23 Physiological Functions of Gi/o and Control by RGS Proteins PI: R. Neubig ($2,403,356 total costs) August 2010 – July 2014 National Institutes of Health R01DA023252-05 Design of Small Molecules Acting at Regulators of G Protein Signaling PI: R. Neubig ($1,250,000 total direct costs) October 2007 – September 2013 National Institutes of Health R01DA023252-05S1 Design of Small Molecules Acting at Regulators of G Protein Signaling PI: R. Neubig ($112,800 total costs) 4
January 2012 – September 2013 Co-I on 4 NIH R01/P01 grants (Lawrence, Traynor, Tesmer, Brosius) Pending:
National Institutes of Health 2R01DA023252-06 Design of small molecules acting at regulators of G protein signaling PIs: R. Neubig & S. Larsen ($2,395,026 total costs) October 2013 – September 2018 National Institutes of Health 1R21GM104650-01 Small molecule stabilizers of RGS2 protein expression PI: R. Neubig ($427,625 total costs) October 2012 – September 2014
Prior:
Michigan Heart Association, 1983-85; 1987-88 Hartford Foundation Fellowship, 1983-86 National Science Foundation, 1984-87 NIH R01 HL37551, 1987-90 NIH R01 HL46417, 1992-2004 NIH, R21 GM59462, 1999-2001 NIH R21 NS057014-01, 2007-2009 NIH R03 MH087441-02 , 2009 –2011 American Heart Association, Established Investigator, 1987-1993 Protein Structure and Design 1994 (Sponsor for J.M. Taylor) AAUW Fellowship 1995 (Sponsor for Joan M. Taylor) NIH GM14654, 1991-1994 (NSRA fellowship for A.E. Remmers) NIH GM19473 1998-1999 (NRSA for Dr. N. Sarvazyan) UMCC Munn Idea Grant 2002 UM Biomedical Tech Transfer Fund 2002-2004 AHA Predoctoral Fellowship 2003-2005 (Ying Fu) UM-ORGS Translational Research Grant, 2005-2007 NIH F32 GM076821-01, Fellowship for David Roman, PhD NSF Biomolecular Interaction Technologies Center (2006-2008) NIH F31 CA113268-2 Fellowship for Chris Evelyn Swedish Research Foundation Fellowship for Benita Sjögren
CERTIFICATION AND LICENSURE Medical Licensure #044798: Michigan (expired 1997) Board Certification: Internal Medicine, 1984 Michigan Pharmacy License (laboratory use): 2011
5
LANGUAGES English – native French – intermediate reading and speaking Japanese – beginning reading and speaking German – beginning reading and speaking MILITARY SERVICE None HONORS AND AWARDS 1972 1972-74 1973 , 1974 1974 1975 1975 1976-77 1976-81 1983-86 1986 1988-93 2003 2007-2011 2009 2013
Phi Eta Sigma Cardiovascular Research Trainee James B. Angell Scholar Phi Beta Kappa American Institutes of Chemists Award High distinction and highest honors in Chemistry Myasthenia Gravis Foundation Fellowship Medical Scientist Traineeship, NIH Hartford Foundation Fellowship Syntex Scholars Program Finalist American Heart Association, Established Investigator Invited Speaker Nobel Forum on G protein coupled receptors Michigan Society of Fellows, H.H. Rackham School of Graduate Studies Astellas Award for Translational Pharmacology, ASPET ASPET-Pharmacia Award in Experimental Therapeutics
MEMBERSHIP AND OFFICES IN PROFESSIONAL SOCIETIES 1975198119861989-91 2002-05
AAAS Biophysical Society ASPET Central Society for Clinical Research ASBMB
COMMUNITY SERVICE Founder
[email protected], e-mail list. 1986 TEACHING ACTIVITIES University of Michigan Basic Science Teaching:
6
Current 2010Past 1984-98 1983 1997-1999 1986 1986-1999 1993-98 1984-92 1994 1986-88 1985 1983-86 2002-2003 1999-2006 1999-2009 1993-2009 2010-2011 2010-2010 2006-2010
Lecturer, Pharmacology 601, Principles of Pharmacology Course Director, Pharmacology 500 (Principles of Pharmacology) Co-Director:1984 & 1993-98 Lecturer, Pharmacology 500 (Principles of Pharmacology) Lecturer, Pharmacology 502 Course Co-Director, LA2U6E (Senior Therapeutics) Lecturer, “ Lecturer, Pharmacology 659 (Pharmacy, Pharmacology) Lecturer, Pharmacology 625 (Medical Pharmacology) Lecturer, M2 Neuroscience Lecturer, Pharmacology 614 (Endocrine Pharmacology) Course Director, Pharmacology 640 (short course on Pharmacology of Ion Channels) Co-Coordinator, Pharmacology Graduate Student Journal Club Lecturer, Pharmacology 611, Principles of Pharmacology Lecturer, Biochemistry 550, Protein Structure and Function Course Co-Director, Pharmacology 610, Receptor Pharmacology Lecturer, M1 Pharmacology, Cardiovascular Autonomic Pharmacology Lecturer, Chemical Biology 502, Signal Transduction Lecturer, Pharmacology 601, Principles of Pharmacology Clinical Fellow Basic Research Summer Laboratory Course
Training Programs: 1985-88 19861991199119912002200320072002-
Neuroscience Training Program Pharmacological Sciences Training Program Biophysics Research Division, Affiliated Faculty Endocrinology and Metabolism Training Grant Multipurpose Arthritis Center Michigan Diabetes Research and Training Center Chemical Biology Initiative Training Program Microfluidics in Biomedical Sciences Training Program Multidisciplinary Cardiovascular Research Training Program – Steering Committee
Mentorship: Postdoctoral: 1988-89 1989-90 1990-96 1993-94
James C. Ferraro, D.O. (private practice) Shompa Datta, Ph.D. Ann Remmers, Ph.D. (Scientist, Arraybiopharma, Boulder CO) Staffan Uhlén, Ph.D. (Professor, University of Bergen, Norway) 7
1995-99 1996-97
2003-2008 2003-2005 2007-2009 2006-2010 20082010-
Noune Sarvazyan, Ph.D. (CEO, Artann Laboratories). Greg Modrall, M.D. (Associate Professor, Surgery, University of Texas, Southwestern) Joseph Bankole Thompson, M.D., Ph.D. (Editor, Michigan Chronicle) Christiaan Brink, Ph.D. (Associate Professor, North-west University Faculty of Health Sciences, Potchefstroom, South Africa) Huailing Zhong, Ph.D. (Staff Scientist, Lundbeck Pharmaceuticals, Paramus, NJ) Xinyan Huang, Ph.D. (Staff Scientist, Lundbeck Pharmaceuticals, Paramus, NJ) Johannes Bodenstein, Ph.D. (Assistant Professor, University of Kwa-Zulu Natal, South Africa) David Roman, Ph.D. (Assistant Professor, University of Iowa) Petar Igic, MD. Ph.D. (Cardiologist, Wisconsin Heart & Vascular Institute) S. Thierry Omouessi Ph.D. (University Henri Poincaré, Nancy, France) Kuljeet Kaur Ph.D. (University of Winnipeg) J. Benita Sjogren, Ph.D. (Karolinska Institutet) Sergio Parra, M.D. (University of Antioquia, Medellín, Colombia)
1999-2001 1999-2004 2001-2002
Visiting Scientists/Faculty John Bisognano, MD, PhD (Internal Medicine) Qin Wang, MD (Pharmacology) Wayne Leifert, PhD (CSIRO, Adelaide, Australia)
1997 1998-1999 1999-2002 2002-2007 2003-2006
Ph.D. Students: 1987 1988 1992 1992 1993 1995 1996 1998 2001 2001 2005 2006 2008 2009 2010
Marian H. Kim, Ph.D. (deceased) William Thomsen, Ph.D. (Director of Molecular Pharmacology, Arena Pharmaceuticals) Mark Gerhardt, M.D., Ph.D. (Associate Professor, Anesthesiology, Ohio State University) Guim Kwon, Ph.D. (Assistant Professor, SIUE School of Pharmacy) D'vorah Graeser, Ph.D. (Scientist, Compugen, Israel) Joan Taylor, Ph.D. (Assoc. Prof., University of North Carolina) Joseph Thompson, M.D., Ph.D. (Editor, Michigan Chronicle) Keng-Li Lan, M.D., Ph.D. (Physician, Taiwan) William K. Lim (Assoc. Prof., University of Malaysia, Sarawak) Duane Chung (Entrepreneur, Toronto, Canada) Peter Clapp (Asst. Prof. Pharmaceutical Sciences, Regis University) Ying Fu (Postdoc, University of Washington) Rebecca Roof (Postdoc, NIH) Chris Evelyn (Postdoc, Univ. Cincinati) Levi Blazer Jason Kehrl Andrew Storaska 8
Andrew Haak M.D. Students: 1989-91 1993, 1994 1996
Hiroko Mori Dalman, M.D. Linda McKenzie Michael Han M.S. Students:
1987 1994 2010
Robin D. Gantzos (Pharmacology) Mark Connolly (Pharmacology) Molly Doyle Muxlow (Med. Chem.) Graduate Student Rotations:
1983 1986-87 1987 1988 1989 1995 1996 1997 1997 1998 1999 1999 2000 2000 2000 2001 2002
David Moliterno Vassia Roulia Lori Mangels Francis Lee Donnalyn Scheuner Jamie Novak Lee Koetzner Dan Linseman Patrick Murphy Yang-Hae Park Dyke McEwen Emily Jutkiewicz Jennifer Harrel Brian Gentry Andrew Haas Ting-Ting Hong Joe Lee (MSTP) (no updates after 2002) Undergraduate Students
1993-94 1994-95 1994-95 19961996-98 1998 1998 1997-98 1999 2000
M.Wayne Sikes (U of M) Partha Mukhopadhyay (U of M) Chris Engel (U of M) Michael Liu (U of M) Dyke McEwen (Kalamazoo College) Jesse Hart (University of Detroit) Tomas Holmqvist (University of Uppsala, Sweden) Paolo Abado (U of M) Erica Riddle (U of M) Danielle Woods (Xavier University) 9
2001 2001 2001-2002 2002 2002 2003 2004-2005 2006 2006 2006 2008 2008 2008 2008 2008 2011 2011
Leighton Janes (Delta State University) Brandy Butcher (Xavier University) Alec Schmaier (Princeton University) Megan Wilbur (Univ of Michigan) Namandjé Bumpus (Occidental College) Eli Iacob (University of Michigan) Tim Ferng (University of Michigan) Shodai Ota (University of Michigan) Jonathan Vandenberg (Albion College) Melvin Rivera (University of Puerto Rico-Rio Piedras) Alfred Chung (University of Michigan) Andrew Kocab (University of Notre Dame) Matthew Stern (Huron High School, Ann Arbor) Erica Nachman (University of Michigan) Hans Dalton (University of Michigan) Kevin Kohut (University of Michigan) Joyce Jih (University of Michigan) Thesis Committees (non-chair):
1985 1986 1987 1987 1987 1987 1987 1987 1988 1988 1989 1989 1989 1989 1989 1989 1990 1990 1991 1992 1993 1993 1993 1995 1994 1994
Stephanie Mitsos (Pharmacology) Sung Ae Lee (Pharmacology) Ron Weishaar (Pharmacology) Terry Jastrow (Neuroscience) Brian Ciliax (Pharmacology) Fred Lamb (Physiology) Eric Richfield (Neuroscience) Ki-Hong Noh (Electrical Engineering) Jeff Harrison (Pharmacology) Janine Larsen (Biomedical Engineering) Patrick Roseboom (Pharmacology) David Eberhard (Pharmacology) Kevin Hutchinson (Biochemistry) Janice Ackerman (Neuroscience) Steve Thomas (Cell and Molecular Biology) Jung-Ho Cha (Neuroscience) Dean Chang (Physiology) Thomas Hornyak (Biological Chemistry) Angela Thompson (Pharmacology) Peter Tummino (Biological Chemistry) Jan Senyshyn (Pharmacology) Andrea Stout (Biophysics) Michelle Dong Wang (Biophysics) Mike Model (Biophysics) Jerry Caldwell (Cell and Molecular Biology) Donnalyn Scheuner (Pharmacology) 10
1994 1995 1995 1995 1995 1995 1996 1997 1997 1997 1999 1999 2000 2000 2001 2001 2001 2003 2003 2003 2005 2005 2005 2005 2005 2006 2006 2006 2007 2008 2009 2009 2010 2010 2010 2010 2010 2010 2010 2010 2011 2011 2011 2013 2013
Yifeng Yuan (Biophysics) Kyle Palmer (Pharmacology) Diana Slowiejko (Pharmacology) Julie Hoffman (Chemical Engineering) Rob Sorenson (Pharmacology) Gayatry Jakob (Chemistry) Ariane McKiernan (Biophysics) Lonnie Shea (Chemical Engineering) William Cho (Neuroscience) Adam Goldsmith (Pharmacology) Christopher Tan (University of Western Ontario) Gregor Zimmerman (Biological Chemistry) Faye Bradbury (Biological Chemistry) Daniel Linseman (Pharmacology) Laura Nelson Johns (Pharmacology) Peter Woolf (Chemical Engineering) Andy Alt (Pharmacology) Carol Fowler (Medicinal Chemistry) Bin Lin (Biology) Adam Hoppe (Biophysics) René Bernard (Pharmacology) Elizabeth Lapozcka (Pharmacology) Bin Yi (Physiology) L’Aurelle Johnson (Pharmacology) Emily Jameson (Chemistry) Bradley Henson (MSTP) Christine Clouser (Biological Chemistry) Irfan Lodhi (MCB) Matt Wharton (Pharmacology) Sean Friday (MCDB) Adam Kuszak (Pharmacology) Rex Jian Pei (Chemistry) Andrew Stelzer (Chemical Biology) Jody Lancia (Chemical Biology) Andreja Jovic (Biomedical Engineering) Yi Chen (Biophysics) Raghu Kainkaryam (Chemical Engineering) Daniel Peltier (Micro/Immuno) Chris Evans (Chemical Biology) David Thal (Chemical Biology) Gisselle Velez (CMB) Bethany Strunk (Chemical Biology) Ben Thompson (Chemistry) Brian DeVree (Chemical Biology) Jennifer Thompson Lamberts (Pharmacology) Janice Sindac (Medicinal Chemistry) Veronica Taylor (Biophysics) 11
2000 2002 2003
External Examiner for Ph.D. Chris Tan (University of Western Ontario) Chi Sum (University of Toronto) Johannes Bodenstein (Potchefstroom University for CHE, South Africa) Clinical Teaching:
1984-86; 1988-94 Attending Physician, Hypertension Outpatient Clinic October 1984; June 1985 Attending Physician, Hypertension Consultation Service August 1985 Attending Physician, Internal Medicine Inpatient Service June 1985 Residents Conference, Adverse Drug Reactions Nov. 1985 Clinicopathologic Conference July 1986 Grand Rounds, Internal Medicine March 1983, February 1986, February 1987, April 1995 - Hypertension Research Conference April 1986 Allergy Research Conference Nov. 1989 Rheumatology Fellow Conference March 1993 " " " March 1995 Michigan Gut Peptide Research Center Conference June 1995 Cardiology Research and Basic Science Lecture Nov. 1998 Neurology Fellows Research Seminar Continuing Medical Education: May 1985 March 1986 Feb 1994 Oct 2006 Jan 2011
Advances in Internal Medicine (Moderator: Hypertension Section) Michigan Hypertension Update: New Antiadrenergic Drugs Panel Discussion: Pharmacological Therapy Meadowbrook Hypertension Workshop, Organizer Human Genetics Conference University of Michigan, Cardiovascular Research Center
EXTRAMURAL INVITED PRESENTATIONS European Society of Neurochemistry, Goteborg, Sweden, June 1988 Workshop: Advances in Second Messengers University of Toronto, Faculty of Pharmacy, Toronto, Ontario, March 1989 University of California, San Diego, Department of Pharmacology and Scripps Research Clinic, LaJolla, CA, May 1989 Vanderbilt University, Department of Pharmacology, Nashville, TN, July 1989 Guest lecturer in course on "Drug Receptor Interactions:" Topic: Nicotinic Acetylcholine Receptors Research Seminar: Topic - 2 Adrenergic Receptors American Society of Anesthesiologists Workshop on Alpha2 Adrenergic Receptors, New Orleans, LA, October 1989 Henry Ford Hospital Endocrinology Resident Research Conference, 12
"Catecholamine Receptors," Detroit, MI, November 1990 University of Illinois, Chicago, April 1991 Medical College of Wisconsin, May 1991 Cardiology Division, Grand Rounds "G Proteins in Clinical Medicine" Physiology Department, "G Proteins in Signal Transduction" Vanderbilt University, Department of Pharmacology, Nashville, TN, July 1991 Guest lecturer in course on "Drug Receptor Interactions:" Topic: Nicotinic Acetylcholine Receptors Research Seminar: Topic - 2 Adrenergic Receptors University of California, San Diego, Department of Pharmacology, La Jolla, CA, November 1991 University of Western Ontario Cardiovascular Research Club: "Mechanisms and Modulation of Receptor G Protein Coupling," November 1991 University of New Mexico, Department of Cellular and Molecular Biology, February 1992 University of Nebraska, Department of Pharmacology, March 1992 Texas A&M, Department of Microvascular Research, April 1992 Meadowbrook Hypertension Conference, Rochester, MI, January 1993 Medical University of South Carolina, Department of Pharmacology, August 1993 Medical College of Ohio, Department of Pharmacology, February 1994 Victor Chang Cardiac Research Institute, Sydney, Australia, March 1994 University of Virginia, Charlottesville, Department of Physiology and Biophysics, May 1994 Medical College of Wisconsin, Department of Pharmacology, June 1994 Merch, Sharp and Dohme, Rahway, NJ, June 1994 IUPHAR, Satellite Symposium on Adrenergic Receptors, Montreal Canada, July, 1994. Baylor University, Department of Physiology and Biophysics, October 1994 CorPharmaceuticals, November 1994 University of Florida, December 1994 University of North Carolina, Department of Physiology, March 1995 Warner Lambert-Parke Davis, March 1995 ASPET Colloquium on 2A Adrenergic Receptors, Nashville, TN, September 1995 International Second Messengers Meeting, Invited workshop participant "Cytoskeleton in Signal Transduction", Nashville, TN, October 1995 Oregon Health Sciences University, Department of Medical Psychology, November 1995 IBC International Symposium on "Structure and Function of G Protein Coupled Receptors" Philadelphia, PA, December 1995 Dupont-Merck Research, December 1995 University of Wisconsin, Madison, WI, March 1996 2nd IBC International Symposium on "Structure and Function of G Protein Coupled Receptors", Philadelphia, PA, October 1996 2nd International Colloquium on Second Messengers and Signal Transduction, Berlin, October 1996 University of Massachusetts, Worcester, March 1997 ASPET Colloquium, Signaling and Macromolecular Structure in Pharmacology, April 1997 Dartmouth Medical School, April 1997 Case Western Reserve University, June 1997 National Minority Research Symposium, New Orleans, LA, October 1997 University of New Mexico, April 1998 University of Uppsala, Sweden, August 1998 Yale University, October 1998 Oregon Health Sciences University, January 1999 13
University of Houston, College of Pharmacy, February 1999 University of Texas Health Sciences Center, San Antonio, February 1999 Emory University, March 1999 University of Virginia, Charlottesville, April 1999 Great Lakes G Protein Coupled Receptor Retreat, November 1999 Gordon Research Conference, 2nd Messengers and Protein Phosphorylation, June 2000 Case Western, Department of Biochemistry, Cleveland, OH, September 2000 University of North Carolina, Department of Pharmacology, Chapel Hill, NC, October 2000 University of Colorado, Department of Pharmacology, Denver CO, November 2000 Columbia University, Department of Pharmacology, New York NY, December 2000 Gordon Research Conference, Molecular Pharmacology, February 2001 Arena Pharmaceuticals, San Diego CA, February 2001 Wyeth-Ayerst Research, Princeton, NJ, April 2001 Inspire Pharmaceuticals, Durham, NC, July 2001 University of North Carolina, Dept. of Pharmacology, Chapel Hill, NC, December 2001 NIDA Conference on Structural Biology, Genomics, and Proteomics, Bethesda, MD, May 2002 Millennium Pharmaceuticals, Cambridge, MA, June 2002 University of Toronto, Toronto, ON, August 2002 Plenary Speaker - Third International Conference on Pharmaceutical and Pharmacological Sciences (ICPPS 2002), Johannesburg, South Africa, September 2002 Purdue University, West Lafayette, IN, November 2002 ASPET, Molecular Pharmacology Postdoc Session, Plenary Speaker, April 2003 University of Wisconsin, Madison, May 2003 University of Illinois, Chicago, May 2003 Nobel Forum on G Protein Coupled Receptors, June 2003 Gordon Research Conference, Second Messengers and Protein Phosphorylation, June 2003 Case Western Medical School, Cleveland, December 2003 NEOUCOM, Department of Physiology & Pharmacology, March 2004 ASPET, RGS Colloquium, April 2004 Biosciences 2004, Glasgow, Scotland, July 2004 IUPHAR Clinical Pharmacology and Toxicology, Brisbane, Australia, Aug 2004 Horizon Symposium (Nature Publishing Group), Verona, Italy, October 2004 Washington University, St. Louis, December 2004 SUNY Stonybrook, March, 2005 EB 2005, HTS Symposium, April 2005 College on Problems of Drug Dependence, Orlando, June, 2005 Berlex GPCR Symposium, October, 2005 Fondation Ipsen, Paris, France, December 2005 FDA Center for Drug Evaluation and Research, January 2006 Wayne State University, Neuroscience, January 2006 Glaxo-Smith-Kline, January 2006 Medical College of Georgia, April 2006 Pfizer, Ann Arbor, MI, May 2006 Scandinavian GPCR Conference, Stockholm Sweden, August 2006 Assay Designs, Ann Arbor, September, 2006 Accuri Cytometers, Ann Arbor, October 2006 Boehringer Ingelheim, Danbury, CT, November 2006 14
NIH, Chemical Genomics Center, June 2007 Gordon Research Conference, G Proteins, June 2007 Epix Pharmaceuticals, Lexington, MA, July 2007 University of New Hampshire, Biomedical Interactions Technology Center July 2007 Abbott Laboratories, Chicago, IL, August 2007 Microsoft Research Center, Trento, Italy, Visiting Professor, September 2007 University of Milan, Department of Pharmacology, Italy, September 2007 Cayman Chemicals, Ann Arbor MI, September 2007 Merck Research Labs, Rahway NJ, October 2007 Johns Hopkins University, Cell Biology, Baltimore, MD, November 2007 Geisinger Clinic, Danville PA, December 2007 University of Iowa, Iowa City, IA, January 2008 Uniformed Services University of the Health Sciences, Bethesda, MD, January 2008 University of North Carolina, Chapel Hill, NC, March 2008 University of Miami, Miami, FL, May 2008 Gordon Conference, G proteins and Phosphorylation, June 2008 Mt. Sinai, School of Medicine, October 2008 NIH Symposium on HTS in Neuroscience, November 2008 Medical University of South Carolina, November 2008 Creighton University, December 2008 University of North Dakota, December 2008 Northwestern University, January 2009 University of Geneva, April 2009 University of Western Ontario, May 2009 University of Chicago, Sept 2009 Rush Medical College, March 2010 International Union of Pharmacology, April 2010 University of Pennsylvania, May 2010 World Pharmaceutical Congress, June 2010 Van Andel Research Institute, July 2010 Great Lakes GPCR Retreat, Toronto, October 2010 UCLA, November 2010 IUPUI, March 2011 Experimental Biology, Wash DC, April 2011 ASPET RGS/AGS Colloquium, Wash DC, April 2011 University of New Hampshire, July 2011 Exeter, UK, October, 2011 Wayne State University, February, 2012 Gordon Research Conference Prot Phos/G Prot Networks, June 2012 Society for Neuroscience, October 2012 University of Southern California, November 2012 University of Iowa, March 2013 Japanese Pharmacological Society, Fukuoka, March 2013 Shanghai Jiaotung University, College of Pharmacy, April 2013
15
COMMITTEE AND ADMINISTRATIVE SERVICE International 2000IUPHAR Receptor Nomenclature Committee (NC-IUPHAR) Vice-chair, GPCRs (2010- ) 1998-2002 Program Committee IUPHAR 2002 (San Francisco) 2010-2014 IUPHAR Nominating Committee National 1997-2002 1994-97 1997-2000 1999-2001 2002-2005 2004-2008 2009-2012 2012-2013
ASPET, Division for Molecular Pharmacology, Executive Committee (Chair 1997-1999) Founding Chair, Molecular Pharmacology Section, ASPET ASPET, Scientific Council ASPET, Membership Advisory Committee ASPET Goodman and Gilman Award Committee ASPET Board of Publications Trustees ASPET Councillor ASPET President-elect
University of Michigan General 1985 Planning Committee, Advances in Internal Medicine 1986-87 Medical Scientist Training Program, Operating Committee 1987-91 Biomedical Research Council (Associate Chair 1989-90; Chair 1990-91) 1989-92 Geriatrics Center Research Committee 1990 Medical School Search Committee for Pharmacology Chair 1993-96 Medical School Committee on Appointments, Promotions and Tenure (Vice Chair, 1994-95; Chair 1995-96) 1993-94 Medical School Focus Group on Future Initiatives 1995 Rackham Research Partnership Biology Section Review Panel 1996 Rackham Predoctoral Fellowship Biology Section Review Panel 1998-99 PIBS Curriculum Committee 1999MSTP Career Advisory Panel 1999Cardiovascular Center, McKay Grants Award Committee 2002 Cardiovascular Center, Research Space Planning Committee 2002-2005 Biophysics Research Division, Executive Committee 2002-2003 Life Sciences Institute, Cell Biology Task Force 2003-2004 Biophysics Research Division, Long Range Planning Committee 2004-2006 Biomedical Research Council 2005-2007 Chair, Medical School Information Technology Faculty Advisory Committee (ITFAC) 2005-2008 Chemical Biology Program, Program Committee/Executive Committee 2005 Warner Lambert Chemistry Chair Search Committee 2008-2010 Faculty Grievance Committee, Cognate Pool 2008-2009 Upjohn Center for Clinical Pharmacology Review, Chair 2009 University of Michigan Drug Discovery Institute Planning Committee, CoChair 16
2010-
Biomedical Research Cores Review Committee
Department of Pharmacology 1983-84 Preliminary Examination Committee (Neuropharmacology) 1985-90 Preliminary Examination Committee (General Principles) 1986 Ad Hoc Committee on Promotions Criteria Promotions Committee 1987-88 Department Review Committee 1987-1997 Departmental Advisory Committee (Chair 1989-90, 1993-94, 1996-97) 1992-95 Pharmacology Computer Committee (Chair, 1993-1994) 1998-1999 Pharmacology Search Committee 1998-1999 Pharmacology Internal Review Committee 1987-88, 95, 97-98, 2000Pharmacology Appointments and Promotions Committee 2003-2010 Awards Committee (chair) 2010Development Committee (co-chair) 2011-2014 Department Advisory Committee 2011Entrepreneurship & Industrial Relations Committee PATENTS & INVENTION DISCLOSURES US #4,883,649: Radioiodinated p-Iodoclonidine, a High Affinity Probe of 2 Receptors. VanDort, M., Counsell, R.E. and Neubig, R.R. US #7,189,519: Bead-based Detection of Ligand-GPCR-G Protein Complexes. Sklar, Buranda, Cimino, Key, Neubig, Simons, Prossnitz, Shi US #7,432,242: Inhibitors of RGS Proteins.Mosberg, H. Neubig, R., Jin, Y. and Zhong, H. US Patent Application: Methods and Compositions for Modulating Rho-Mediated Gene Transcription (Serial No.: 13/496,827, Filing Date: March 16, 2012) US Patent Application: No. 61/243,370 Methods and Compositions for Inhibiting Rhomediated Diseases and Conditions World Patent Application: Small Molecule Inhibitors of RGS Proteins (PCT/US12/35474, Filing date 27-APR-2012) UM Invention Disclosure: File 2051 Fluorescence RGS Assay by [35S] GTPS Binding UM Invention Disclosure: File 2157 Peptide RGS Inhibitors (Mosberg et al) UM Invention Disclosure: File 2349 Fluorescence RGS Assay by BODIPY GTPS Binding UM Invention Disclosure: File 2991 Gi2 RGS-insensitive Mouse Model UM Invention Disclosure: File 2994 Small Molecule Inhibitors of Rho Signaling UM Invention Disclosure: File 3582 M-Screen High-throughput screening informatics system UM Invention Disclosure: File 4427 Small Molecule Inhibitors of Rho Transcriptional Signaling UM Invention Disclosure: File 4667 Inducible RGS4-expressing cell lines UM Invention Disclosure: File 4782 Small molecule inhibitors of RGS proteins UM Invention Disclosure: File 5647 Inhibitors of Rho signaling 17
BIBLIOGRAPHY Completed Publications in Scientific Journals Peer Reviewed Publications 1. Neubig RR, and Hoobler SW: Reversal of chronic renal hypertension: Role of salt and water excretion. Proc Soc Exp Biol Med 150:254-256, 1975. 2. Neubig RR, Krodel EK, Boyd ND, and Cohen JB: Acetylcholine and local anesthetic binding to Torpedo nicotinic postsynaptic membranes after removal of nonreceptor peptides. Proc Natl Acad Sci USA 76:690-694, 1979. 3. Neubig RR, and Cohen JB: Equilibrium binding [3H]acethylcholine by Torpedo postsynaptic membranes: interactions. Biochemistry 18:5464-5475, 1979.
of [3H]tubocurarine and Stoichiometry and ligand
4. Neubig RR, and Cohen JB: Permeability control by cholinergic receptors in Torpedo postsynaptic membranes: Agonist dose-response relations measured at second and millisecond times. Biochemistry 19:2770-2779, 1980. 5. Froehner SC, Gulbrandsen V, Hyman C, Jeng AY, Neubig RR, and Cohen JB: Immunofluorescence localization at the mammalian neuromuscular junction of the Mr 43,000 protein of Torpedo postsynaptic membranes. Proc Natl Acad Sci USA 78:52305234, 1981. 6. Neubig RR, Boyd ND, and Cohen JB: Conformations of the Torpedo acetylcholine receptor associated with ion transport and desensitization. Biochemistry 21:3460-3467, 1982. 7. Egan B, Neubig R, and Julius S: Pharmacologic reduction of sympathetic drive increases platelet alpha2-receptor number. Clin Phar Ther 38:519-523, 1985. 8. Neubig RR, Gantzos RD, and Brasier RS: Agonist and antagonist binding to 2 adrenergic receptors in purified membranes from human platelets. Implications of receptor-Ni stoichiometry. Mol Pharmacol 28:475-486, 1985. 9. Kim MH, and Neubig RR: Parallel inactivation of 2 adrenergic agonist binding and Ni by alkaline treatment. FEBS Lett 192:321-325, 1985. 10. Neubig RR, and Szamraj O: Large scale purification of 2 adrenergic receptor enriched membranes from human platelets. Persistent association of guanine nucleotides with unpurified membranes. Biochem Biophys Acta 854:67-76, 1986. 11. Bittner MA, Holz RW, and Neubig RR: Guanine nucleotide effects on catecholamine secretion from digitonin-permeabilized adrenal chromaffin cells. J Biol Chem 261;1018210188, 1986. 12. Kim MH, and Neubig RR: Membrane reconstitution of high affinity 2 adrenergic agonist binding by purified guanine nucleotide binding proteins. Biochemistry 26:3664-3672, 1987. 18
13. VanDort M, Neubig RR, and Counsell RE: Radioiodinated p-iodoclonidine: A high affinity probe for the alpha2 adrenergic receptor. J Med Chem 30:1241-1244, 1987. 14. Neubig RR, Gantzos RD, and Thomsen WJ: Mechanism of agonist and antagonist binding to 2 adrenergic receptors. Evidence for a precoupled receptor-guanine nucleotide protein complex. Biochemistry 37:2374-2384, 1988. 15. Gantzos RD, and Neubig RR: Temperature effects on 2 adrenergic receptor-Gi interactions. Biochemical Pharmacology 37:2815-2821, 1988. 16. Thomsen WJ, Jacquez JA, and Neubig RR: Inhibition of adenylate cyclase is mediated by the high affinity conformation of the 2 adrenergic receptor. Molecular Pharmacology 34:814-822, 1988. 17. Supiano MA, Neubig RR, Linares OH, Halter JB, and Rosen, SG: Effects of low sodium diet on regulation of platelet 2 adrenergic receptors in young and elderly humans. Am J Physiol 256:E339-E344, 1989. 18. Kjeldsen SE, Neubig RR, Weder AB, and Zweifler AJ: The hypertension-coronary heart disease dilemma: The catecholamine-blood platelet connection. J Hypertens 7:851-860, 1989. 19. Thomsen WJ, and Neubig RR: Rapid kinetics of 2 adrenergic inhibition of adenylate cyclase: Evidence for a distal rate limiting step. Biochemistry 28:8778-8786, 1989. 20. Zamorski MA, Ferraro JC, and Neubig RR: Subcellular distribution of 2 adrenergic receptors, pertussis toxin substrate and adenylate cyclase in human platelets. Biochem J 265:755-762, 1990. 21. Neubig RR, and Thomsen WJ: How does a key fit a flexible lock? Structure and dynamics in receptor function. Bioessays 11:136-142, 1989. 22. Michel MC, Regan JW, Gerhardt MA, Neubig RR, Insel PA, and Motulsky HJ: Nonadrenergic [3H]idazoxan binding sites are physically distinct from 2-adrenergic receptors. Mol Pharm 37:65-68, 1990. 23. Gerhardt MA, Wade SM, and Neubig RR: [125I]p-Iodoclonidine is a partial agonist at the 2 adrenergic receptor. Mol Pharm 38:214-221, 1990. 24. Sekkarie MA, Egan B, Neubig RR, and Supiano MA: Sensitization of human 1 and 2 adrenergic venous responses by guanadrel sulfate. Clin Pharm Ther 5:537-543, 1990. 25. Dalman HM, and Neubig RR: Two peptides from the alpha2-adrenergic receptor alter receptor G protein coupling by distinct mechanisms. J Biol Chem 266:11025-11029, 1991. 26. Gerhardt MA, and Neubig RR: Multiple Gi subtypes regulate a single effector mechanism. Mol. Pharmacol 40:707-711, 1991. 27. Mangels LA, Neubig RR, and Gnegy ME: Differential calmodulin binding behavior of purified subunits in activated guanine nucleotide regulatory proteins. Biochem J 283:683-690, 1992. 19
28. Omann GM, Harter JM, Hassan N, Mansfield PJ, Suchard SJ, and Neubig RR: A threshold level of coupled G-proteins is required to transduce neutrophil responses. J Immunol 149(6):2172-2178, 1992. 29. Kwon G, Remmers A, Datta S, and Neubig RR: Synthesis and characterization of fluorescently labelled subunits of brain G proteins. Biochemistry 32:2401-2408, 1993. 30. Remmers A, and Neubig RR: Resonance energy transfer from fluorescent G protein subunits to membrane lipids. Biochemistry 32:2409-2414, 1993. 31. Graeser D, and Neubig RR: Limited access of receptors to G proteins in NG108-15 cells: Lack of cross-talk in agonist binding among the alpha2 adrenergic, muscarinic and opiate receptors. Mol Pharmacol 43:434-443, 1993. 32. Neubig RR, and Sklar LA: Subsecond modulation of formyl-peptide-linked G proteins by GTPS in permeabilized neutrophils. Mol Pharmacol 43:734-740, 1993. 33. Zuiderweg ERP, vanDoren SR, Kurochkin AV, Neubig RR, and Majumdar A: Model NMR spectroscopy of proteins and peptides in solution and its relevance to drug design. Perspectives in Drug Discovery and Design 1:391-417, 1993. 34. Taylor JM, Jacob-Mosier GG, Lawton RG, and Neubig RR: Coupling an alpha2-adrenergic receptor peptide to G-protein. A new photolabeling agent. Peptides 15:829-834, 1994. 35. Remmers AE, Posner R, and Neubig RR: Fluorescent guanine nucleotide analogs and G protein activation. J Biol Chem 269:13771-13778, 1994. 36. Wade SM, Yang S-Z, Dalman HM, and Neubig RR: Multisite interactions of receptors and G proteins. Enhanced potency of dimeric receptor peptides in modifying G protein function. Mol Pharmacol 45:1191-1197, 1994. 37. Kwon G, Axelrod D, and Neubig RR: Lateral mobility of tetramethylrhodamine (TMR) labelled G protein and submits in NG 108-15 cells. Cell Signalling 6:663-679, 1994. 38. Neubig RR: Membrane organization in G protein mechanisms. FASEB J 8:939-946, 1994. 39. Taylor JM, Jacob-Mosier GG, Lawton RG, Remmers AE, and Neubig RR: Binding of an 2-adrenergic receptor third intracellular loop peptide to Gand the amino terminus of G . J Biol Chem 269:27618-27624, 1994. 40. Taylor JM, and Neubig RR: Peptides as probes for G protein signal transduction. Cell Signal 6:841-849, 1994. 41. Uhlén S, Porter AC, and Neubig RR: The novel alpha-2 adrenergic radioligand [3H]MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exo Ther 271:1558-1565, 1994.
20
42. Kjeldsen SE, Weder AB, Egan B, Neubig RR, Zweifler AJ, and Julius S: Effect of circulating epinephrine on platelet function and hematocrit. Hypertension 25:1096-1105, 1995. 43. Connolly MC, Remmers AE, and Neubig RR: Rapid kinetics of G protein subunit association: A rate-limiting conformational charge? FEBS Letters 355:251-253, 1995. 44. Marin EP, and Neubig RR: Lack of G-protein beta2- and gamma2-subunit N-terminal fragments provides evidence against the coiled-coil model of beta-gamma subunit assembly. Biochem J 309:377-380, 1995. 45. Wade SM, Scribner MK, Dalman HM, Taylor JM, and Neubig RR: Structural requirements for Go activation by receptor-derived peptides: Activation and modulation domains of the 2-adrenergic receptor i3c region. Mol Pharm 50:351-358, 1996. 46. Remmers AE, and Neubig RR: Partial G protein activation by fluorescent guanine nucleotide analogs. Evidence for a triphosphate-bound but inactive state. J Biol Chem 271:4791-4804, 1996. 47. Taylor JM, VanDort M, Jacob-Mosier G, Lawton RG, and Neubig RR: Receptor and membrane interaction sites on G. A receptor-derived peptide binds to the carboxyterminus. J Biol Chem 271:3336-3339, 1996. 48. Remmers AE, and Neubig RR: Partial G protein activation by fluorescent guanine nucleotide analogs. Evidence for a triphosphate-bound but inactive state. J Biol Chem 271:4791-4804, 1996. 49. Diverse-Pierluissi M, Remmers AE, Neubig RR, and Dunlap K. Novel form of crosstalk between G protein and tyrosine kinase pathways. Proc Natl Acad Sci USA 94:5417-5421, 1997. 50. Zhu M, Neubig RR, Wade SM, Posner P, Gelband CH, Sumners C: Modulation of K+ and Ca2+ currents in cultured neurons by an angiotensin II Type 1a receptor peptide. Am J Physiol Cell Physiol 273:C1040-C1048, 1997. 51. Lan K-L, Remmers AE, Neubig RR: Role of Go tryptophans in GTP hydrolysis, GDP release, and fluoroscence signals. Biochemistry 37:837-843, 1998. 52. Sarvazyan NA, Remmers AE, and Neubig RR: Determinants of Gi1 and -gamma binding. Measuring high affinity interactions in a lipid environment using flow cytometry. J Biol Chem 273:7934-7940, 1998. 53. Lan K-L, Sarvazyan NA, Taussig R, MacKenzie RG, DiBello PR, Dohlman HG, and Neubig RR: A point mutation in Go and Gi1 blocks interaction with regulator of G protein signaling proteins. J Biol Chem 273:12794-12797, 1998. 54. Thompson JB, Wade SM, Salafranca, MN, Harrison JK, and Neubig RR: Co-expression of second and third intracellular loop fragments inhibits angiotensin AT1a receptor activation of phospholipase C in HEK293 cells. J Pharm Exp Ther 285:216-222, 1998. 55. Wade SM, Lim WK, Lan LK, Chung D, Nanamori M, and Neubig RR. 1999. Gi activator region of 2A adrenergic receptors: Distinct basic residues mediate Gi vs Gs activation. Mol Pharmacol 56:1005-1013, 1999. 21
56. Remmers AE, Engel C, Liu M, and Neubig RR. Interdomain interactions regulate GDP release from heterotrimeric G proteins. Biochemistry 38:13789-800, 1999. 57. Sullivan SM, Mishra R, Neubig RR, and Maddock, JR. Analysis of guanine nucleotide binding and exchange kinetics of Escherichia coli GTPase Era. Journal of Bacteriology. 182: 3460-3466, 2000. 58. Brink CB, Wade SM, and Neubig, RR. Agonist-directed trafficking of porcine -adrenerigc receptor signaling in CHO cells. l-Isoproterenol selectively activates Gs. J Pharmacol Exp Ther. 294:539-547 2000. 59. Stanasila L, Lim WK, Neubig RR, and Pattus F. Coupling efficacy and selectivity of the human mu-opioid receptor expressed as receptor-G alpha fusion proteins in Escherichia coli. J Neurochem. 75: 1190-1199, 2000. 60. Lan KL, Zhong H, Nanamori M, and Neubig RR. Rapid Kinetics of Regulator of G-protein Signaling (RGS) - Mediated Gi and Go Deactivation: G Specificity of RGS4 and RGS7. J Biol Chem.. 275: 33497-33503, 2000. 61. Shea LD, Neubig RR and Linderman JJ. Timing is everything the role of kinetics in G protein activation. Life Sci. 68:647-58, 2000. 62. Park IK, Klug CA, Li K, Jerabek L, Li L, Nanamori M, Neubig RR, Hood L, Weissman IL and Clarke MF. Molecular cloning and characterization of a novel regulator of G- protein signaling from mouse hematopoietic stem cells. J Biol Chem. 276:915-23, 2001. 63. Lapinski PE, Neubig RR, and Raghavan M. Walker A lysine mutations of TAP1 and TAP2 interfere with peptide translocation but not peptide binding. J Biol Chem. 276:7526-33, 2001. 64. Lim WK, and Neubig RR. Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein) alpha and betagamma subunits by urea. Biochem J. 354: 337-44, 2001. 65. Wade SM, Lan K, Moore DJ, and Neubig RR. Inverse agonist activity at the alpha(2A)adrenergic receptor. Mol Pharmacol. 59:532-42, 2001. 66. McEwen DP, Gee KR, Kang HC and Neubig RR. Fluorescent BODIPY-GTP analogs: realtime measurement of nucleotide binding to G proteins. Anal Biochem. 291:109-17, 2001. 67. Bennett TA, Key TA, Gurevich VV, Neubig R, Prossnitz ER and Sklar LA. Real-time analysis of G protein-coupled receptor reconstitution in a solubilized system. J Biol Chem. 276:22453-60, 2001. 68. Zhong H and Neubig RR. Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther. 297:837-45, 2001 69. Modrall JG, Nanamori M, Sadoshima J, Barnhart DC, Stanley JC, and Neubig RR. ANG II type 1 receptor downregulation does not require receptor endocytosis of G protein coupling. Am J Physiol Cell Physiol. 281:C801-9, 2001. 70. Lim WK, Myung CS, Garrison JC and Neubig RR. Receptor-G protein gamma specificity: gamma 11 shows unique potency for A(1) adenosine and 5-HT(1A) receptors. Biochemistry 40:10532-41, 2001.
22
71. Seta K, Nanamori M, Modrall JG, Neubig RR and Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem. 277:9268-77, 2002. 72. Chung DA, Wade SM, Fowler CB, Woods DD, Abada PB, Mosberg HI and Neubig RR. Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochem Biophys Res Commun. 293:1233-41, 2002. 73. Chung DA, Zuiderweg ERP and Neubig RR.. NMR Structure of the Second Intracellular Loop of the 2a Adrenergic Receptor: Evidence for a Novel Cytoplasmic Helix. Biochemistry 41:3596-604, 2002. 74. Neubig RR and Siderovski DP. Regulators of G protein signaling as new central nervous system drug targets. Nature Reviews Drug Discovery 1: 187 – 197, 2002 75. Soyer O, Dimmic MW, Neubig RR and Goldstein RA. Using evolutionary methods to study G-protein coupled receptors. Pac Symp Biocomput. 2002, 625-36, 2002 76. Wang Q, Liu M, Mullah B, Siderovski DP, and Neubig RR. Receptor-selective effects of endogenous RGS3 and RGS5 to regulate MAP kinase activation in rat vascular smooth muscle cells. J Biol Chem. 277: 24949-24958, 2002. 77. Neubig RR. Regulators of G protein signaling (RGS proteins): Novel central nervous system drug targets. J Pept Res. 60:312-6, 2002. 78. Yoo J, Yang Y, Choi I, Shangguan Y, Song I, Neubig RR, and Wiley J. Expression of novel splice variants of the G protein subunit, G(o)alpha, is tissue-specific and age-dependent in the rat. Gene, 296: 249, 2002. 79. Sarvazyan, N.A., Lim, W.K., and Neubig, R.R. 2002. Fluorescence analysis of receptor-G protein interactions in cell membranes. Biochemistry, 41:12858-67. 80. Zhong H, Wade SM, Woolf PJ, Linderman JJ, Traynor JR and Neubig RR. A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) proteinmediated kinetic scaffolding. J Biol Chem. 278: 7278-84, 2003. 81. Clark MJ, Harrison C, Zhong H, Neubig RR, and Traynor JR. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adrenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J Biol Chem. 278: 9418-25, 2003. 82. Goubaeva F, Ghosh M, Malik S, Yang J, Hinkle PM, Griendling KK, Neubig RR and Smrcka AV. Stimulation of cellular signaling and G protein subunit dissociation by G protein beta gamma subunit binding peptides. J Biol Chem. 278:19634-41, 2003. 83. Soyer OS, Dimmic MW, Neubig RR, Goldstein RA. Dimerization in aminergic G-proteincoupled receptors: application of a hidden-site class model of evolution. Biochemistry. 42: 14522-31, 2003. 84. Chai BX, Neubig RR, Millhauser GL, Thompson DA, Jackson PJ, Barsh GS, Dickinson CJ, Li JY, Lai YM, Gantz I. Inverse agonist activity of agouti and agouti-related protein. Peptides. 2003, 24:603-9. 23
85. Jameson EE, Cunliffe JM, Neubig RR, Sunahara RK, and Kennedy RT. Detection of G Proteins by Affinity Probe Capillary Electrophoresis Using a Fluorescently Labeled GTP Analogue Anal. Chem. 2003, 75: 4297-4304.
86. Shangguan Y, Hall KE, Neubig RR, Wiley JW. Diabetic neuropathy: inhibitory G protein dysfunction involves PKC-dependent phosphorylation of Goalpha. J Neurochem. 2003 86:1006-14. 87. Simons PC, Shi M, Foutz T, Cimino DF, Lewis J, Buranda T, Lim WK, Neubig RR, McIntire WE, Garrison J, Prossnitz E, Sklar LA. Ligand-receptor-G-protein molecular assemblies on beads for mechanistic studies and screening by flow cytometry. Mol Pharmacol. 2003 64:1227-38. 88. Neubig RR, Spedding M, Kenakin T, Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003 55: 597606. 89. Soyer OS, Dimmic MW, Neubig RR, Goldstein RA. Dimerization in aminergic G-proteincoupled receptors: application of a hidden-site class model of evolution. Biochemistry. 2003 Dec 16;42(49):14522-31. 90. Simons PC, Biggs SM, Waller A, Foutz T, Cimino DF, Guo Q, Neubig RR, Tang WJ, Prossnitz ER, Sklar LA. Real-time analysis of ternary complex on particles: direct evidence for partial agonism at the agonist-receptor-G protein complex assembly step of signal transduction. J Biol Chem. 2004 Apr 2;279(14):13514-21. 91. Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI. Structure-based design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors.J Pept Res. 2004 Feb;63(2):141-6. 92. Clark MJ, Neubig RR, Traynor JR. Endogenous Regulator of G Protein Signaling Proteins Suppress Galphao-Dependent, micro-Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. J Pharmacol Exp Ther. 2004 Jul;310(1):215-22. 93. Wang Q, Liu M, Kozasa T, Rothstein JD, Sternweis PC, Neubig RR. Thrombin and Lysophosphatidic Acid Receptors Utilize Distinct rhoGEFs in Prostate Cancer Cells. J Biol Chem. 2004 Jul 9;279(28):28831-4. 94. Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI. Structure-based Design, Synthesis, and Activity of Peptide Inhibitors of GRS4 GAP Activity. Methods of Enzymol. 2004; 389:266-77. 95. Wang Q, Liu M, Kozasa T, Rothestein JD, Sternweis PC, Neubig RR. Ribozyme- and siRNA- Mediated Suppression of RGS-Containing RhoGEF Proteins. Methods of Enzymol. 2004; 389:229-43 96. Fu Y, Zhong H, Nanamori M, Mortensen RM, Huang X, Lan K, Neubig RR. RGS-Insensitive G-Protein Mutations to Study the Role of Endogenous RGS Proteins. Methods Enzymol. 2004; 389-229-43. 97. Whelan RJ, Sunahara RK, Neubig RR, Kennedy RT. Affinity assays using fluorescence anisotrophy with capillary electrophoresis separation. Anal Chem. 2004 76:7380-6. 24
98. Jameson EE, Roof RA, Whorton MR, Mosberg HI, Sunahara RK, Neubig RR, Kennedy RT. Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues. J Biol Chem. 280:7712-9, 2004 99. Chai BX, Pogozheva ID, Lai YM, Li JY, Neubig RR, Mosberg HI, Gantz I. Receptorantagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors. Biochemistry. 2005 44:3418-31. 100. Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE, D'Silva NJ. Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem. 280:22564-71, 2005 101. Foord SM, Bonner TI, Neubig RR, Rosen EM, Pin JP, Davenport AP, Spedding M, Harmar AJ. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List. Pharmacol Rev. 2005 57:279-288. 102. Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005 57:541-6. 103. Fu Y, Huang X, Zhong H, Mortensen RM, D'Alecy LG, Neubig RR. Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects. Circ Res. 2006 98:659-66. 104. Myung CS, Lim WK, DeFilippo JM, Yasuda H, Neubig RR, Garrison JC. Regions in the G protein gamma subunit important for interaction with receptors and effectors. Mol Pharmacol. 2006 69:877-87. 105. Roof RA, Jin Y, Roman DL, Sunahara RK, Ishii M, Mosberg HI, Neubig RR. Mechanism of Action and Structural Requirements of Constrained Peptide Inhibitors of RGS Proteins. Chem Biol Drug Des. 2006 67:266-74. 106. Huang X, Fu Y, Charbeneau RA, Saunders TL, Taylor DK, Hankenson KD, Russell MW, D'Alecy LG, Neubig RR. Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele. Mol Cell Biol. 2006 Sep;26(18):6870-9. 107. Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol Pharmacol. 2007 Jan;71(1):169-75. 108. Walter NG, Meiners JC, Meyhofer E, Neubig RR, Sunahara RK, Perkins NC, Steel DG, Swanson JA. Under the microscope: Single molecule symposium at the University of Michigan, 2006. Biopolymers. 2007 Feb;85(2):106-14. 109. Jameson EE, Pei J, Wade SM, Neubig RR, Milligan G, Kennedy RT., Capillary electrophoresis assay for G protein-coupled receptor-mediated GTPase activity. Anal Chem. 2007 Feb 1;79(3):1158-63. 110. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, Spedding M. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. Pharmacol Rev. 2007 Mar;59(1):5-13.
25
111. Bodenstein J, Sunahara RK, Neubig RR. N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in HEK293 cells. Mol Pharmacol. 2007 Apr;71(4):1040-50. 112. Rovati GE, Capra V, Neubig RR. The Highly Conserved DRY Motif of Class A GPCRs: Beyond the Ground State. Mol Pharmacol. 2007 Apr;71(4):959-64. 113. Fu Y, Huang X, Piao L, Lopatin A, Neubig RR. Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2532-9. 114.
Vadakkadathmeethal K, Cunliffe JM, Swift J, Kennedy RT, Neubig RR, Sunahara RK. Fluorescence-based adenylyl cyclase assay adaptable to high throughput screening. Comb Chem High Throughput Screen. 2007 May;10(4):289-98.
115. Skrabanek L, Murcia M, Bouvier M, Devi L, George SR, Lohse MJ, Milligan G, Neubig R, Palczewski K, Parmentier M, Pin JP, Vriend G, Javitch JA, Campagne F, Filizola M. Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics. 2007 May 30;8:177. 116. Evelyn CR, Wade SM, Wang Q, Wu M, Iñiguez-Lluhí JA, Merajver SD, Neubig RR. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007 Aug;6(8):2249-60. 117. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature. 2007 Oct 11;449(7163):721-5. 118. Lutz S, Shankaranarayanan A, Coco C, Ridilla M, Nance MR, Vettel C, Baltus D, Evelyn CR, Neubig RR, Wieland T, Tesmer JJ. Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science. 2007 Dec 21;318(5858):1923-7. 119. Huang X, Charbeneau RA, Fu Y, Kaur K, Gerin I, MacDougald OA, Neubig RR. Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gnai2 allele. Diabetes. 57(1):77-8, 2008. 120. Pei J, Dishinger JF, Roman DL, Rungwanitcha C, Neubig RR, Kennedy RT. Microfabricated Channel Array Electrophoresis for Characterization and Screening of Enzymes Using RGS-G Protein Interactions as a Model System. Anal Chem. 2008, Jul 1;80(13):5225-31. 121. Roof RA, Sobczyk-Kojiro K, Turbiak AJ, Roman DL, Pogozheva ID, Blazer LL, Neubig RR*, Mosberg HI*. (These authors contributed equally to this work.) Novel Peptide Ligands of RGS4 from a One-Bead, One-Compound Library. Chemical Biology and Drug Discovery, 2008 Aug;72(2):111-9. 26
122. Shankaranarayanan A, Thal DM, Tesmer VM, Roman DL, Neubig RR, Kozasa T, Tesmer JJ. Assembly of high order Galpha q-effector complexes with RGS proteins. J Biol Chem. 2008 Oct 20. [Epub ahead of print] PMID: 18936096 123. Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR, Greenhill SD, Hale VA, Sharman JL, Bonner TI, Catterall WA, Davenport AP, Delagrange P, Dollery CT, Foord SM, Gutman GA, Laudet V, Neubig RR, Ohlstein EH, Olsen RW, Peters J, Pin JP, Ruffolo RR, Searls DB, Wright MW, Spedding M. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res. 2008 Oct 23. [Epub ahead of print] PMID: 18948278 124. Bernsteel DJ, Roman DL, Neubig RR. In vitro protein kinase activity measurement by flow cytometry. Anal Biochem. 2008 Dec 15;383(2):180-5.. PMID: 18796290 125. Guptaroy B, Zhang M, Bowton E, Binda F, Shi L, Weinstein H, Galli A, Javitch JA, Neubig RR, Gnegy ME. A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol Pharmacol. 2009 Mar;75(3):514-24. PMID: 19098122 126. Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacol Rev. 2009 61(1):1-8. PMID: 19325074 127. Peng W, Peltier DC, Larsen MJ, Kirchhoff PD, Larsen SD, Neubig RR, Miller DJ. Identification of Thieno[3,2-b]Pyrrole Derivatives as Novel Small Molecule Inhibitors of Neurotropic Alphaviruses. J Infect Dis. 199(7):950-7. PMID: 19239364 128. High-Throughput Screening for Small-Molecule Inhibitors of LARG-Stimulated RhoA Nucleotide Binding via a Novel Fluorescence Polarization Assay. Evelyn CR, Ferng T, Rojas RJ, Larsen MJ, Sondek J, Neubig RR. J Biomol Screen. 2009 Feb;14(2):161-72. PMID: 19196702 129. RGS Protein Suppression of G{alpha}o Protein-Mediated {alpha}2A Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity. Goldenstein BL, Nelson BW, Xu K, Luger EJ, Pribula JA, Wald JM, O'Shea LA, Weinshenker D, Charbeneau RA, Huang X, Neubig RR, Doze VA. Mol Pharmacol. Mol Pharmacol. 2009 May;75(5):1222-30. 130. Huang X, Fu Y, Charbeneau RA, Neubig RR. GNAI2 and regulators of G protein signaling as a potential Noonan syndrome mechanism. Med Hypotheses. 73:56-9 PMID: 19282110 131. Roman DL, Ota S, Neubig RR. Polyplexed Flow Cytometry Protein Interaction Assay: A Novel High-Throughput Screening Paradigm for RGS Protein Inhibitors. J Biomol Screen. 2009 Jul;14(6):610-9. PMID: 19531661 27
132. Roof RA, Roman DL, Clements ST, Sobczyk-Kojiro K, Blazer LL, Ota S, Mosberg HI, Neubig RR. A covalent peptide inhibitor of RGS4 identified in a focused one-bead, one compound library screen. BMC Pharmacol. 2009 May 22;9:9. PMID: 19463173 133. Aittaleb M, Gao G, Evelyn CR, Neubig RR, Tesmer JJ. A conserved hydrophobic surface of the LARG pleckstrin homology domain is critical for RhoA activation in cells. Cell Signal. 2009 Nov;21(11):1569-78. Epub 2009 Jun 26. PMID: 19560536 134. Icaza EE, Huang X, Fu Y, Neubig RR, Baghdoyan HA, Lydic R. Isoflurane-induced changes in righting response and breathing are modulated by RGS proteins. Anesth Analg. 2009 Nov;109(5):1500-5.PMID: 1984378 135. Evelyn CR, Bell JL, Ryu JG, Wade SM, Kocab A, Harzdorf NL, Hollis Showalter HD, Neubig RR, Larsen SD. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 20(2):665-72. PMID: 19963382 136. Talbot JN, Roman DL, Clark MJ, Roof RA, Tesmer JJ, Neubig RR, Traynor JR. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent. J Neurochem. 2010 Feb;112(4):1026-34. PMID: 20002516 137. Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM, Huang X, Neubig RR, Traynor JR. RGS inhibition at G(alpha)i2 selectively potentiates 5HT1A-mediated antidepressant effects. Proc Natl Acad Sci U S A. 2010 Jun 15; 107(24):11086-91. PMID: 20534514 138. Khelashvili G, Dorff K, Shan J, Camacho-Artacho M, Skrabanek L, Vroling B, Bouvier M, Devi LA, George SR, Javitch JA, Lohse MJ, Milligan G, Neubig RR, Palczewski K, Parmentier M, Pin JP, Vriend G, Campagne F, Filizola M. GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics. 2010 Jul 15;26(14):1804-5. May 25.PMID: 20501551 139. Roman DL, Blazer LL, Monroy CA, Neubig RR. Allosteric Inhibition of the Regulator of G Protein Signaling-G{alpha} Protein-Protein Interaction by CCG-4986. Mol Pharmacol. 2010 Sep;78(3):360-5. PMID: 20530129 140. Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, Neubig RR. Reversible, allosteric small-molecule inhibitors of regulator of g protein signaling proteins. Mol Pharmacol. 2010 Sep;78(3):524-33. PMID: 20571077
28
141. Murai K, Qiu R, Zhang H, Wang J, Wu C, Neubig RR, Lu Q. Galpha Subunit Coordinates with Ephrin-B to Balance Self-Renewal and Differentiation in Neural Progenitor Cells. Stem Cells. 2010 Sep;28(9):1581-9. PMID: 20629171 142. Signarvic RS, Cierniewska A, Stalker TJ, Fong KP, Chatterjee MS, Hess PR, Ma P, Diamond SL, Neubig RR, Brass LF. RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood. 2010 Dec 23;116(26):6092-100. Epub 2010 Sep 17.PMID: 20852125 143. Jovic A, Howell B, Cote M, Wade SM, Mehta K, Miyawaki A, Neubig RR, Linderman JJ, Takayama S. Phase-locked signals elucidate circuit architecture of an oscillatory pathway. PLoS Comput Biol. 2010 Dec 23;6(12):e1001040.PMID: 21203481 144. Blazer LL, Zhang H, Casey EM, Husbands SM, Neubig RR. A nanomolar-potency small molecule inhibitor of regulator of g-protein signaling proteins. Biochemistry. 2011 Apr 19;50(15):3181-92. PMID: 21329361 145. Waterson RE, Thompson CG, Mabe NW, Kaur K, Talbot JN, Neubig RR, Rorabaugh BR. Gi2-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart. Cardiovasc Res. 2011 Jul 1;91(1):45-52. 146. Jovic A, Wade SM, Miyawaki A, Neubig RR, Linderman JJ, Takayama S. Hi-Fi transmission of periodic signals amid cell-to-cell variability. Mol Biosyst. 7:2238-44 2011. PMID: 21559542 147. Fribley AM, Cruz PG, Miller JR, Callaghan MU, Cai P, Narula N, Neubig RR, Showalter HD, Larsen SD, Kirchhoff PD, Larsen MJ, Burr DA, Schultz PJ, Jacobs RR, Tamayo-Castillo G, Ron D, Sherman DH, Kaufman RJ. Complementary cell-based highthroughput screens identify novel modulators of the unfolded protein response. J Biomol Screen. 2011 Sep;16(8):825-35. PMID: 21844328 148. Ma P, Cierniewska A, Signarvic R, Cieslak M, Kong H, Sinnamon AJ, Neubig RR, Newman DK, Stalker TJ, Brass LF. A newly-identified complex of spinophilin and the tyrosine phosphatase, SHP-1, modulates platelet activation by regulating G proteindependent signaling. Blood. 2012 Feb 23;119(8):1935-45. PMID: 22210881 149. Li P, Neubig RR, Zingarelli B, Borg K, Halushka PV, Cook JA, Fan H. Toll-like Receptor-Induced Inflammatory Cytokines are Suppressed by Gain of Function or Overexpression of Gα (i2) Protein. Inflammation. 35(5):1611-7. 2012 PMID: 22581266 150. Jacob RT, Larsen MJ, Larsen SD, Kirchhoff PD, Sherman DH, Neubig RR. MScreen: An Integrated Compound Management and High-Throughput Screening Data Storage and Analysis System. J Biomol Screen. 17(8):1080-7 2012 PMID: 22706349
29
151. Sjögren B, Parra S, Heath LJ, Atkins KB, Xie Z, Neubig R. Cardiotonic Steroids Stabilize RGS2 Protein Levels. Mol Pharmacol. 82(3):500-9. 2012. PMID: 22695717 152. Visovatti SH, Hyman MC, Bouis D, Neubig R, McLaughlin VV, Pinsky DJ. Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One. 2012;7(7):e40829. PMID: 22792409 153. Cho H, Kamenyeva O, Yung S, Gao JL, Hwang IY, Park C, Murphy PM, Neubig RR, Kehrl JH. The Loss of RGS Protein-Gαi2 Interactions Results in Markedly Impaired Mouse Neutrophil Trafficking to Inflammatory Sites. Mol Cell Biol. 32(22):4561-71. 2012. PMID: 22966200 154. Lim WK, Kanelakis KC, Neubig RR. Regulation of G protein signaling by the 70kDa heat shock protein.Cell Signal. 2013 Feb;25(2):389-96. Epub 2012 Nov 12. PMID: 23153586 Invited Reviews 1. Neubig, RR: Specificity of receptor G protein coupling: Protein structure and cellular determinants. Seminars in Neurosci 9:189-197, 1998. 2. Traynor JR, Neubig RR. Regulators of G Protein Signaling and Drugs of Abuse. Mol Interv. 2005 5(1):30-41. 3. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, Spedding M. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev. 2007 Mar;59(1):5-13. 4. Blazer, L. and Neubig, R.R. Small Molecule Protein-Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles. Neuropsychopharmacology Reviews, Neuropsychopharmacology. 2009 Jan;34(1):126-41. PMID: 18800065 5. Sjögren B, Blazer LL, Neubig RR. Regulators of G Protein Signaling Proteins as Targets for Drug Discovery. Prog Mol Biol Transl Sci. 2010;91C:81-119. PMID: 20691960 6. Sjögren B, Neubig RR. Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. Mol Pharmacol. 2010 Oct;78(4):550-7. Epub 2010 Jul 27. Review.PMID: 20664002 7. Sjögren B, Blazer LL, Neubig RR. Regulators of G protein signaling proteins as targets for drug discovery. Prog Mol Biol Transl Sci. 2010;91:81-119. Review.PMID: 20691960 8. Kaur K, Kehrl JM, Charbeneau RA, Neubig RR. RGS-insensitive Gα subunits: probes of Gα subtype-selective signaling and physiological functions of RGS proteins. Methods Mol Biol. 2011;756:75-98. Review.PMID: 21870221 Non-Peer-Reviewed Publications 1. Neubig RR: Panic attacks and phobias (Letter). N Engl J Med 308:342, 1983. 30
2. Egan B, Neubig R, Schneider R, and Julius S: Methods for measuring vascular and nonvascular -receptor sensitivity in man. J Cardiovasc Pharmacol 7:5153-5158, 1985. 3. Gerhardt MA, and Neubig RR: p[125I]Iodoclonidine: A new, high specific activity 2adrenergic receptor ligand. DuPont Biotech Update, p. 11, Nov. 1989. 4. Uhlén S, Axelrod D, Keefer JR, Limbird LE, and Neubig RR: Membrane organization and mobility of 2 adrenergic receptors in MDCK cells. Pharmacol Commun 6:155-167, 1995. 5. Nature Reviews Drug Discovery GPCR Questionnaire Participants, The State Of GPCR Research In 2004, Nature Reviews, Drug Discovery 577, 2004 6. Neubig RR. Missing links: Mechanisms of Protean Agonism (Relates to article by Lane, et al., Fast Forward 7 February 2007). Mol Pharmacol. 2007, 71(5):1200-2. 7. Neubig RR. And the winner is…RGS4! Circ. Res. 2008, 103(5):444-6. 8. Motulsky HJ, Neubig RR. Analyzing binding data. Curr Protoc Neurosci. 2010 Jul;Chapter 7:Unit 7.5.PMID: 20578035 9. Blazer LL, Roman DL, Muxlow MR, Neubig RR. Use of flow cytometric methods to quantify protein-protein interactions. Curr Protoc Cytom. 2010 Jan;Chapter 13:Unit 13.11.115.PMID: 20069525 10. Neubig RR. Mind your salts: when the inactive constituent isn't. Mol Pharmacol. 2010 Oct;78(4):558-9. Epub 2010 Jul 22. Review.PMID: 20651116
Articles Submitted for Publication 1. S. Thierry Omouessi, Raelene A. Charbeneau, Susan M. Wade, and Richard R. Neubig Reduced growth hormone function and enhanced insulin sensitivity in mice with an RGSinsensitive Gαi2 mutation. Mol Cell Endocrinol, submitted. 2. Sergio Parra, Xinyan Huang, Raelene A. Charbeneau, Susan M. Wade, Kuljeet Kaur, Boyd R. Rorabaugh, Richard R. Neubig, Generation and Characterization of Conditional Knock-in Mice with Enhanced Gi2 Signaling, Physiological Genomics, submitted 3. Books 1.
Pharmacology of G Protein Coupled Receptors. Editor R. Neubig. Volume 62 in ADVANCES IN PHARMACOLOGY Series Editor S. J. Enna. Academic Press, 2011. ISBN 13: 978-0-12-385952-5
Chapters in Books
31
1. Cohen JB, Boyd ND, Jeng AY, Medynski DC, Neubig RR, St. John P, and Shera NS: Permeability control by Torpedo acetylcholine receptors. In: Yamamura, Olsen and Usdin (eds): Psychopharmacology and Biochemistry of Neurotransmitter Receptors (New York, NY: Elsevier North Holland, 1980), 47-62. 2. Neubig, RR and Thomsen, WJ: "Rapid kinetics of 2 adrenergic agonist binding", In: Goheen S (ed): Membrane Proteins: Proceedings of the Membrane Protein Symposium (San Diego, California: BioRad, 1987), 619-632. 3. Neubig RR: Time course of drug action. In: Pratt WB, and Taylor P (eds): Principles of Drug Action (New York, NY: Churchill Livingstone, 1990), 297-363. 4. Graeser CA, and Neubig RR: Methods for the study of receptor/G protein interactions. In: Milligan G (ed): G Protein-Mediated Signal Transduction: A Practical Approach (Oxford, UK: IRL Press, 1991), 1-30. 5. Neubig RR: Drug-Receptor Interaction. In: DiPalma JR (ed): Basic Pharmacology in Medicine. 4th Edition (Medical Surveillance Inc., 1994), Chapter 2, 16-27. 6. Motulsky HJ, and Neubig RR: Analysis of radioligand binding data. In: Crawley J, Gerfen C, McKay R, Rogawski M, Sibley D, and Skolnick P (eds): Current Protocols in Neuroscience (New York, NY: John Wiley & Sons, 1997), 7.5.1-7.5.55. 7. Neubig RR, Taylor JM, Wade SM, Yang S-Z: 2a Adrenergic receptor peptides and G proteins: Structure and Mechanism: In: Lanier SM and Limbird LE (eds): 2 Adrenergic Receptors: Structure, Function and Therapeutic Implications (Harwood Academic Publishers, Amsterdam, 1997), 19-29. 8. Neubig, R.R. Peptides as tools for the study of Receptor/G protein interactions: In: Receptor Biochemistry and Methodology (series eds. C. Strader and D. Sibley) Vol. III – Structure Function Analysis of G Protein Coupled Receptors J. Wess (ed.), (Wiley Liss, 1999), pp. 205-232. 9. McEwen, DC, Gee, KC, Hee, CK Neubig, RR Fluorescence approaches to study G protein mechanisms: In Methods in Enzymology, (eds. Hildebrandt, J. and Iyengar, R.) Methods Enzymol. 344:403-20, 2002 10. Qin Wang, Min Liu, Tohru Kozasa, Jeffrey D. Rothstein, Paul C. Sternweis, and Richard R. Neubig Ribozyme- and siRNA-mediated suppression of RGS-containing RhoGEF proteins, Methods in Enzymology, in press. 11. Ying Fu, Huailing Zhong, Masakatsu Nanamori, Richard M. Mortensen, Xinyan Huang, Kengli Lan, and Richard R. Neubig RGS-insensitive G protein Mutations to Study the Role of Endogenous RGS Proteins, Methods in Enzymology, 2004.
32
12. Yafei Jin, Huailing Zhong, John R. Omnaas, Richard R. Neubig and Henry I. Mosberg, Structure-Based Design, Synthesis, and Pharmacological Evaluation of Peptide Inhibitors of RGS4 GAP Activity, Methods in Enzymology, 2004. 13. Blazer LL, Roman DL, Muxlow MR, Neubig RR. Use of flow cytometric methods to quantify protein-protein interactions. Curr Protoc Cytom. 2010 Jan;Chapter 13:Unit 13.11.1-15. Abstracts, Preliminary Communications, Panel Discussions Not listed Audio-Visual Educational Materials 1.PHARMKIN - A Pharmacokinetics Simulation, 1985, 1987. 2.PHARMKIN version 2, 1992. 3.Beta Blocker Therapy of Hypertension (TV tape with Dr. A. Zweifler), 1986. 4.Sitemaker Web Development System (with Jonathan Maybaum): http://sitemaker.umich.edu Neubig CV January 2013
33
